UBS Group Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective reduced by analysts at UBS Group from $768.00 to $633.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s price objective points to a potential upside of 7.29% from the stock’s previous close.

Several other research analysts have also recently weighed in on REGN. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. The Goldman Sachs Group lowered their target price on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. TD Cowen reduced their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Piper Sandler lowered their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Finally, Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $892.60.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $590.00 on Wednesday. The company has a market cap of $64.50 billion, a P/E ratio of 15.41, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals has a 1 year low of $525.99 and a 1 year high of $1,211.20. The stock’s fifty day moving average price is $628.85 and its 200-day moving average price is $714.29.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the firm earned $9.55 earnings per share. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently bought and sold shares of REGN. Capital International Investors lifted its holdings in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after purchasing an additional 155,369 shares during the last quarter. Dodge & Cox boosted its holdings in shares of Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock worth $1,653,543,000 after purchasing an additional 9,381 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after purchasing an additional 810,144 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock valued at $1,456,864,000 after buying an additional 149,124 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.